文献速递神经眼科

COVID-19感染与疫苗的神经眼科不良事件:一项全国性队列研究

Neuro-Ophthalmic Adverse Events of COVID-19 Infection and Vaccines: A Nationwide Cohort Study.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

这项全国性人群回顾性队列研究纳入8,498,353例患者,分为对照组、COVID-19感染组和COVID-19疫苗接种组,分析早期(60天内)和晚期(61-180天)神经眼科不良事件的发生率与风险比。结果显示,眼睑下垂与COVID-19疫苗接种相关(早期HR=1.65,晚期HR=2.02),且BNT162b2的眼睑下垂风险低于ChAdOx1;吉兰-巴雷综合征/Miller Fisher综合征与COVID-19感染相关(早期HR=5.97);其他神经眼科不良事件与感染或疫苗接种无显著关联。

要点

  • 眼睑下垂在疫苗接种组早期HR=1.65、晚期HR=2.02,均高于对照组。
  • BNT162b2疫苗的眼睑下垂风险低于ChAdOx1疫苗。
  • GBS/MFS在COVID-19感染组早期HR=5.97,高于对照组。

核心结论

  • 眼睑下垂与COVID-19疫苗接种相关,尤其与ChAdOx1疫苗相关;GBS/MFS与COVID-19感染相关;其他神经眼科不良事件与感染或疫苗接种无关联。

研究设计与样本

  • 全国性人群回顾性队列研究,纳入8,498,353例患者,分为对照组、COVID-19感染组和COVID-19疫苗接种组,分别分析早期(60天内)和晚期(61-180天)神经眼科不良事件的发生率与风险比。

主要发现

  • 除眼睑下垂和GBS/MFS外,其他神经眼科不良事件在COVID-19感染后未见显著增加,且发生率极低。
  • 眼睑下垂在疫苗接种组早期HR=1.65、晚期HR=2.02,均显著高于对照组。
  • BNT162b2疫苗的眼睑下垂风险低于ChAdOx1疫苗。
  • GBS/MFS在COVID-19感染组早期HR=5.97,显著高于对照组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the association of COVID-19 infection and vaccination with neuro-ophthalmic adverse events. METHODS: In this nationwide population-based retrospective cohort study, 8,498,353 patients were classified into three groups: control, COVID-19 infection, and COVID-19 vaccination. We conducted separate analyses for the early phase (within 60 days) and late phases (61-180 days) to estimate the incidence rates and hazard ratio (HR) for each neuro-ophthalmic adverse event. The adverse events included in this analysis were optic neuritis, papilledema, ischemic optic neuropathy, third nerve palsy, fourth nerve palsy, sixth nerve palsy, facial palsy, nystagmus, ptosis, blepharospasm, anomalies of pupillary function, and Guillain-Barré syndrome/Miller Fisher syndrome (GBS/MFS). RESULTS: Neuro-ophthalmic adverse events other than ptosis and GBS/MFS exhibited no significant increase after COVID-19, and their incidence was extremely low. The incidence rate of ptosis in both phases was significantly higher in patients administered COVID-19 vaccination (HR = 1.65 in the early phase and HR = 2.02 in the late phase) than in the control group. Additionally, BNT162b2 conferred a lower ptosis risk than ChAdOx1. GBS/MFS had a significantly higher incidence rate in the early phase (HR = 5.97) in patients with COVID-19 infection than in the control group. CONCLUSIONS: Ptosis was associated with COVID-19 vaccination, particularly with the ChAdOx1 vaccine, while GBS/MFS was associated with COVID-19 infection. In contrast, no association was found between other neuro-ophthalmic adverse events and COVID-19 infection or vaccination. These results may provide helpful insights for diagnosing and treating the neuro-ophthalmological adverse events after COVID-19.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Han JY, Kim S, Han J, et al. Neuro-Ophthalmic Adverse Events of COVID-19 Infection and Vaccines: A Nationwide Cohort Study. Invest Ophthalmol Vis Sci. 2023. PMID: 38010696. doi:10.1167/iovs.64.14.37

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。